Save 20% on All Global Market Reports With Code ONLINE20 – Gain Insights Into Tariffs, Inflation, and Industry Trends
What Is the Growth Potential of the Behcets disease Market in the Next Decade?
The behcets disease market size has grown strongly in recent years. It will grow from $1.15 billion in 2024 to $1.24 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing awareness of rare diseases, availability of biologic treatments, growing healthcare infrastructure, rising prevalence of autoimmune diseases, and growing adoption of biologic therapies.
The behcets disease market size is expected to see strong growth in the next few years. It will grow to $1.67 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing research on autoimmune and inflammatory diseases, growing number of clinical trials and research studies, development of personalized therapies, expanding patient access to healthcare in emerging markets and increasing focus on patient-centric care models. Major trends in the forecast period include advancements in diagnostic techniques, advancements in precision medicine, shift towards telemedicine and digital health solutions, growing collaboration between pharmaceutical companies and research institutions, and novel combination therapies for treatment.
Claim your free report sample now:
What Are the Key Growth Factors Supporting the Behcets disease Market Expansion?
The increasing healthcare investment in rare diseases is expected to propel the growth of the behcets disease market going forward. Rare diseases refer to disorders that affect fewer than 1 in 2,000 people, often involving complex symptoms and limited treatment options. Increasing healthcare investment in rare diseases is primarily driven by the growing recognition of unmet medical needs, as many patients lack effective treatments, prompting governments and pharmaceutical companies to prioritize research, development, and funding in this area. Behçet's disease exemplifies how focused research and advocacy in a single rare condition can catalyze broader investment in rare diseases, demonstrating that targeted efforts can drive significant advancements in understanding, treatment, and policy for the entire rare disease community. For instance, in April 2024, according to Global Genes, a US-based nonprofit organization, in the first quarter of 2024, companies developing drugs for rare diseases raised $7.1 billion through public equity and debt financings, a 307% surge compared to the $1.8 billion raised in the same period of 2023. Therefore, the increasing healthcare investment in rare diseases is driving the growth of the behcets disease market.
Which Segments Are Attracting Maximum Investment in the Behcets disease Market?
The behcets disease market covered in this report is segmented –
1) By Treatment Type: Corticosteroids, Immunosuppressants, Biologics, Other Treatments
2) By Route Of Administration: Oral, Injectable, Topical
3) By Type of Disease: Non-Ocular Behcet’s Disease, Ocular Behcet’s Disease
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Corticosteroids: Oral Corticosteroids, Topical Corticosteroids, Intravenous Corticosteroids
2) By Immunosuppressants: Methotrexate, Azathioprine, Cyclophosphamide, Mycophenolate Mofetil, Cyclosporine
3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors
4) By Other Treatments: Colchicine, Thalidomide, Hydroxychloroquine, Corticosteroid-Sparing Agents
What Are the Significant Trends in the Behcets disease Market Across Regions?
Major companies operating in the behcets disease market are focusing on conducting clinical trials to develop innovative products such as innate defense regulator (IDR) to enhance immune system modulation and offer more effective treatments for inflammation and other symptoms associated with the disease. Innate defense regulators (IDRs) are synthetic peptides that modulate the innate immune response by enhancing the body's natural defense mechanisms, and in the case of Behçet's disease, they help by regulating the immune system to reduce excessive inflammation, potentially alleviating symptoms and controlling flare-ups. For instance, in November 2024, Soligenix, Inc., a US-based biopharmaceutical company, initiated patient enrollment for its Phase 2 study (protocol number DUS-AUBD-01), evaluating SGX945 (dusquetide) in the treatment of Behçet's disease. This study aims to assess the potential of SGX945, an innate defense regulator (IDR), to modulate the immune system and reduce inflammation, offering a novel therapeutic approach to managing the symptoms and flare-ups associated with behçet's disease.
Which Major Companies Are Operating in the Behcets disease Market?
Major companies operating in the behcets disease market are AbbVie Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Chugai Pharmaceutical Co. Ltd, Sun Pharmaceutical Industries Limite, Eisai Co. Ltd, Pharmascience Inc, Samsung Bioepis Co. Ltd., Maxivision Eye Hospitals Pvt. Ltd, Ainos Inc., Soligenix Inc, XOMA Corporation, Creabilis S.A., Iltoo Pharma S.A.S., Ganzhou Hemay Pharmaceutical Co. Ltd., Sanguine Biosciences Inc., NYU Langone Health
Get the full behcets disease market report here:
How Is Regional Performance Expected to Affect Behcets disease Market Growth?
North America was the largest region in the behcets disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the behcets disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment